Michael W. Weiner is a pioneering researcher in the use of neuroimaging and biomarkers for Alzheimer's disease diagnosis and tracking. As director of the Alzheimer's Disease Neuroimaging Initiative (ADNI) and leader of numerous large-scale multi-site studies, Dr. Weiner has transformed how Alzheimer's disease is diagnosed and monitored in clinical practice and research.<sup>1</sup>
Michael W. Weiner is a pioneering researcher in the use of neuroimaging and biomarkers for Alzheimer's disease diagnosis and tracking. As director of the Alzheimer's Disease Neuroimaging Initiative (ADNI) and leader of numerous large-scale multi-site studies, Dr. Weiner has transformed how Alzheimer's disease is diagnosed and monitored in clinical practice and research.<sup>1</sup>
Biography
Dr. Weiner completed his medical training and radiology residency at UCSF, where he also pursued research training in nuclear medicine and neuroimaging. He has been a professor at UCSF since 1985, where he founded and directs the Center for Imaging of Neurodegenerative Diseases (CIND). He has led ADNI since its inception in 2004, coordinating over 50 sites across North America and Europe.<sup>1,2</sup>
Research Focus
Dr. Weiner's research has revolutionized Alzheimer's disease diagnosis and monitoring through neuroimaging and biomarkers:
ADNI Leadership
Established the Alzheimer's Disease Neuroimaging Initiative (ADNI), the largest Alzheimer's imaging study
Standardized MRI and PET protocols used worldwide for AD research
Created public databases used by thousands of researchers globally
Neuroimaging
MRI: Developed techniques for measuring hippocampal atrophy and white matter changes
PET: Pioneered amyloid and [tau](/proteins/tau) PET imaging for AD diagnosis
Advanced Methods: Diffusion tensor imaging, functional MRI, and ASL perfusion
Biomarkers
Established cerebrospinal fluid biomarker protocols for AD
Validated blood-based biomarkers for screening and monitoring
Integrated biomarker data with imaging for comprehensive patient characterization
Clinical Trials
Led neuroimaging components of numerous AD clinical trials
Developed imaging endpoints for disease-modifying therapies
Established protocols for monitoring treatment response
Notable Contributions
ADNI Foundation: Established the largest AD imaging database
Standardization: Created worldwide imaging standards for AD research
Biomarker Validation: Validated CSF and blood biomarkers
Trial Design: Improved imaging endpoints for clinical trials
Key Publications
Weiner MW, et al. "The Alzheimer's Disease Neuroimaging Initiative: a review of papers published in 2011-2012." Alzheimers Dement. 2013;9(5):e68-e73. PMID: 23932184(https://pubmed.ncbi.nlm.nih.gov/23932184/)
Jack CR, et al. "Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers." Lancet Neurol. 2013;12(2):207-216. PMID: 23375564(https://pubmed.ncbi.nlm.nih.gov/23375564/)
Awards and Recognition
MetLife Foundation Award
American College of Radiology Distinguished Researcher Award
[PubMed: Michael Weiner](https://pubmed.ncbi.nlm.nih.gov/?term=Weiner+MW+alzheimer)
Background
The study of Michael W. Weiner has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Recent Research (2024-2026)
Connell E et al. [A novel Mediterranean diet-inspired supplement reduces hippocampal amyloid deposits and microglial activation through the modulation of the microbiota gut-brain axis in 5xFAD mice](https://doi.org/10.1080/19490976.2026.2614030). Gut microbes. 2026;:.
Lv X et al. [Blautia coccoides-derived metabolite trimethylamine-N-oxide exacerbates Alzheimer's disease progression via targeting HIF1α signaling](https://doi.org/10.1080/19490976.2025.2605768). Gut microbes. 2026;:.
Wang RM et al. [lncRNAs: key player in Aβ deposition](https://doi.org/10.1080/15476286.2026.2639017). RNA biology. 2026;:.
Imaizumi LFI et al. [Cognitive load alters cortical dynamics during gait in Parkinson's disease but not in neurologically healthy individuals](https://doi.org/10.1007/s11571-026-10424-4). Cognitive neurodynamics. 2026;:.
Research Contributions
Mermaid diagram (expand to render)
References
[Weiner MW, et al., The Alzheimer's Disease Neuroimaging Initiative. Alzheimers Dement. 2013 (2013)](https://pubmed.ncbi.nlm.nih.gov/23932184/)
[Veitch DP, et al., ADNI 2019 update on recruitment. Alzheimers Dement. 2019 (2019)](https://pubmed.ncbi.nlm.nih.gov/31659337/)
[Jack CR, et al., Dynamic biomarkers of Alzheimer's disease. Lancet Neurol. 2013 (2013)](https://pubmed.ncbi.nlm.nih.gov/23375564/)